Peetz Christopher 4

4 · Mirum Pharmaceuticals, Inc. · Filed Jul 8, 2026

AI-generated summary of this filing

Updated Jul 8, 2026

Mirum (MIRM) CEO Christopher Peetz Sells $2.45M Shares, Exercises Options

What Happened

Christopher Peetz, CEO of Mirum Pharmaceuticals (MIRM), exercised stock options and sold shares on July 6, 2026. He exercised 20,000 options at $2.94 each (cost $58,720) and the filing reports a separate derivative disposition of 20,000 shares at $0.00 (the filing does not explain the zero value). On the same date he sold 20,000 shares in four open-market transactions for aggregate proceeds of $2,445,383.

Key Details

Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely)
Sales breakdown (open market):
- 12,134 shares @ $121.65 = $1,476,101 (wtd avg; range $121.11–$122.105)
- 4,181 shares @ $122.34 = $511,504 (wtd avg; range $122.13–$123.1125)
- 1,975 shares @ $123.74 = $244,387 (wtd avg; range $123.24–$124.10)
- 1,710 shares @ $124.79 = $213,391 (wtd avg; range $124.27–$124.94)
- Total sold: 20,000 shares for $2,445,383
Option exercise: 20,000 shares acquired at $2.94 each for $58,720; option fully vested (footnote F6)
Additional derivative entry: 20,000 shares reported disposed at $0.00 (filing gives no further detail)
Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 2, 2026 (footnote F1)
Shares owned after the transactions: not specified in the provided filing excerpt

Context

The filing shows an exercise of options and contemporaneous sales totaling the same number of shares (20,000 acquired vs. 20,000 sold). This pattern is common when executives exercise options and sell shares under a prearranged plan; the Form 4 does not state the settlement mechanics.
Sales under a 10b5-1 plan are typically pre-scheduled and generally viewed as routine rather than an ad hoc signal of sentiment; purchases (which can be a stronger bullish signal) were limited to the option exercise here.

Form 4

Period: 2026-07-06

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Exercise/Conversion
Common Stock
2026-07-06$2.94/sh+20,000$58,720→ 214,309 total
Sale
Common Stock
[F1][F2]
2026-07-06$121.65/sh−12,134$1,476,101→ 202,175 total
Sale
Common Stock
[F1][F3]
2026-07-06$122.34/sh−4,181$511,504→ 197,994 total
Sale
Common Stock
[F1][F4]
2026-07-06$123.74/sh−1,975$244,387→ 196,019 total
Sale
Common Stock
[F1][F5]
2026-07-06$124.79/sh−1,710$213,391→ 194,309 total
Exercise/Conversion
Employee Stock Option (right to buy)
[F6]
2026-07-06−20,000→ 108,487 total
Exercise: $2.94Exp: 2029-03-11→ Common Stock (20,000 underlying)

Holdings

Footnotes (6)

[F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
[F2]The weighted average sale price for the transaction reported was $121.65, and the range of prices were between $121.11 and $122.105. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F3]The weighted average sale price for the transaction reported was $122.34, and the range of prices were between $122.13 and $123.1125. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F4]The weighted average sale price for the transaction reported was $123.74, and the range of prices were between $123.24 and $124.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F5]The weighted average sale price for the transaction reported was $124.79, and the range of prices were between $124.27 and $124.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F6]The stock option is fully vested.

Signature

/s/ Judit Ryvkin, Attorney-in-Fact|2026-07-08

1 file